CLS presents poster at 9th Annual Brain Mets Congress in Marseille, France, 4-5 October
Clinical Laserthermia Systems AB (publ) will participate in the 9th Annual Brain Metastases Research and Emerging Therapy Conference in Marseille, France, 4-5 October, presenting a poster titled “Laser thermal therapy for brain metastases: Ex vivo and in vivo validation in an ovine brain model”, demonstrating that the TRANBERG®|Thermal Therapy System is suited for highly precise and reliable ablation in brain tissue.
- We are very pleased to get the opportunity to present our initial tests with the TRANBERG®|Thermal Therapy System, including the new MR thermometry software,in this format and in front of such a qualified audience. Together with our partners, MRI Interventions and Image Guided Therapy, we will continue this work with the aim to show that LITT has the potential to become a widely applied therapy in neurosurgery, says Lars-Erik Eriksson, CEO at CLS.
The background of the poster is the the fact that minimally invasive laser-induced interstitial thermal therapy (LITT) is becoming an alternative to conventional surgical management of brain metastases and other pathologies. Recently, at U. S. Food and Drug Administration, the question has surfaced as to the efficacy and reliability of commercially available magnetic resonance (MR) thermometry software. CLS is in cooperation with its two partners, MRI Interventions and Image Guided Therapy, developing a new real-time MR thermometry software. The work, described in the poster, was aimed to characterize the performance of a non-cooled 1064-nm diode laser ablation system in a large animal brain model and investigate the precision of this new real-time MR thermometry software.
The ex vivo and in vivo validation shows that the TRANBERG®|Thermal Therapy System is suited for highly precise and reliable ablation in ovine brain tissue. The laser technology enables tailoring of heat distribution depending on tumour size. Utilizing MR thermometry will protect sensitive structures (e.g., eloquent cortex) and provide approximately every 10 second a tissue damage calculation overview. This ensures essential precision for treating brain tumours. Further evaluation will show the potential of LITT to become a widely applied therapy in neurosurgery.
The authors of the poster are: Verena Knappe, VP Business Development Europe, CLS GmbH, Chris Osswald, Senior Clinical Specialist, Portfolio Manager Ablation Technologies, MRI Interventions, Cristina Pantaleone, Technical Manager Product Development, CLS AB, and Emily Emilsson Rossander, R&D Scientist, CLS AB.
After the meeting the poster will be published on www.clinicallaser.com/posters.
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: firstname.lastname@example.org
Clinical Laserthermia Systems AB (publ),develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Germany and USA, is listed Nasdaq First North Growth Market under the ticker CLS B. Certified Adviser: Certified adviser (CA) isFNCA Sweden AB, Ph: +46 8 528 00 399. E-mail: email@example.com. Further information is available on www.clinicallaser.se